Loading...

FITC anti-mouse CD80 Antibody FITC anti-mouse CD80 Antibody

Pricing & Availability
Clone
16-10A1 (See other available formats)
Regulatory Status
RUO
Other Names
B7-1, B7, Ly-53
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
16-10A1
LPS-stimulated (3 days) BALB/c splenocytes stained with 16-10A1 FITC
  • 16-10A1
    LPS-stimulated (3 days) BALB/c splenocytes stained with 16-10A1 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
104705 50 µg DKK422
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104706 500 µg DKK1212
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD80 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD80 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD80 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD80 appears to be expressed later in the immune response than CD86. CD80 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Reported Reactivity
Dog
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
CHO cell line transfected with mouse B7 (CD80)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation2, in vitro and in vivo blocking of CTLA-4 Ig to CD80 by blocking costimulation of T cells by activated B cells2-4, and immunohistochemical staining of acetone-fixed frozen sections1,4. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104747-104752).

Application References
  1. Harlan DM, et al. 1994. P. Natl. Acad. Sci. USA 91:3137. (IHC)
  2. Razi-Wolf Z, et al. 1992. P. Natl. Acad. Sci. USA 89:4210. (Block, IP)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  5. Ma XT, et al. 2006. Cancer Res. 66:1169.
  6. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC)
  7. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  8. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  9. Misra RS, et al. 2010. J. Exp Med. 207:1775. PubMed
  10. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  11. Philipsen L, et al. 2013. Mol Cell Proteomics. 12:2551. PubMed
Product Citations
  1. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  2. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  3. Wang H, et al. 2022. J Nanobiotechnology. 20:513. PubMed
  4. Kimura Y, et al. 2023. Front Immunol. 14:1070196. PubMed
  5. Vesin B, et al. 2022. Mol Ther. 30:2984. PubMed
  6. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  7. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  8. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  9. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  10. Brigo N, et al. 2023. Cells. 12:. PubMed
  11. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  12. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  13. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  14. Kawai H, et al. 2021. Asian Pac J Allergy Immunol. :. PubMed
  15. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  16. Kis-Toth K, et al. 2011. J Immunol. 187:1273. PubMed
  17. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  18. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  19. Gravano D, et al. 2011. PLoS One. 6:e13517. PubMed
  20. Porciello N, et al. 2018. Nat Commun. 9:1080. PubMed
  21. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  22. Liang F, et al. 2021. RSC Adv. 11:35331. PubMed
  23. Matsumura F, et al. 2021. J Immunol. 207:938. PubMed
  24. Saito S, et al. 2020. Nutrients. 12:. PubMed
  25. Hreha TN, et al. 2020. Front Immunol. 1.597916667. PubMed
  26. Sun T, et al. 2018. Front Immunol. 9:1245. PubMed
  27. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
  28. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  29. Dolgova EV, et al. 2022. Int J Mol Sci. 23:. PubMed
  30. Wang G, et al. 2021. Nat Commun. 12:5733. PubMed
  31. Bode K, et al. 2020. Cell Reports. 29(13):4435-4446.e9.. PubMed
  32. Kimura A, et al. 2018. J Exp Med. 215:2197. PubMed
  33. Jiang H, et al. 2018. Front Pharmacol. 9:612. PubMed
  34. Blank A, et al. 2021. J Pathol. 253:160. PubMed
  35. Li X, et al. 2014. PLoS One. 9:108192. PubMed
  36. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  37. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  38. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  39. Kornstädt L, et al. 2021. Front Immunol. 11:607048. PubMed
  40. Pandey V, et al. 2021. eLife. 0.416666666666667. PubMed
  41. Balashov L 2015. Mult Scler. 21: 1131-1138. PubMed
  42. Liang Y, et al. 2014. J Immunol. 192:1277. PubMed
  43. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  44. Wang J, et al. 2021. Nat Commun. 12:6198. PubMed
  45. Zhou Y, et al. 2020. Front Pharmacol. 10:1579. PubMed
  46. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  47. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  48. Li Y, et al. 2021. Sci Transl Med. 13:. PubMed
  49. Li X, et al. 2009. PLoS One. 4:e6385. PubMed
  50. Cheng Y, et al. 2020. PLoS Pathog. 16:e1008569. PubMed
  51. Ji W, et al. 2018. Evid Based Complement Alternat Med. 2017:3272649. PubMed
  52. Xiong W, et al. 2022. Adv Sci (Weinh). 9:e2103029. PubMed
  53. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  54. Gómez LA, et al. 2020. Front Microbiol. 11:1586. PubMed
  55. Benhamron S, et al. 2012. PLoS One. 7:e35602. PubMed
  56. Sanchez M et al. 2017. Cell host & microbe. 22(4):543-551 . PubMed
  57. Cianciaruso C, et al. 2020. Cell Reports. 27(10):3062-3080.e11.. PubMed
  58. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  59. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
  60. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  61. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  62. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  63. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  64. Zheng B, et al. 2021. Bioact Mater. 6:3879. PubMed
  65. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  66. Ren S, et al. 2022. Int J Biol Sci. 18:166. PubMed
  67. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  68. Nicolas-Boluda A, et al. 2021. eLife. 10:00. PubMed
  69. Wawrzyniak M, et al. 2021. Pharmacol Res Perspect. 9:e00837. PubMed
  70. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  71. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  72. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  73. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
  74. Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
  75. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  76. Funk KE, et al. 2021. Aging Cell. 20:e13412. PubMed
  77. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  78. Sadiq BA, et al. 2020. Current Protocols in Immunology. 131(1):e115. PubMed
  79. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  80. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  81. Wang H, et al. 2022. J Nanobiotechnology. 20:513. PubMed
  82. Kimura Y, et al. 2023. Front Immunol. 14:1070196. PubMed
  83. Vesin B, et al. 2022. Mol Ther. 30:2984. PubMed
  84. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  85. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  86. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  87. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  88. Brigo N, et al. 2023. Cells. 12:. PubMed
  89. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  90. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  91. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  92. Kawai H, et al. 2021. Asian Pac J Allergy Immunol. :. PubMed
  93. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  94. Kis-Toth K, et al. 2011. J Immunol. 187:1273. PubMed
  95. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  96. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  97. Gravano D, et al. 2011. PLoS One. 6:e13517. PubMed
  98. Porciello N, et al. 2018. Nat Commun. 9:1080. PubMed
  99. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  100. Liang F, et al. 2021. RSC Adv. 11:35331. PubMed
  101. Matsumura F, et al. 2021. J Immunol. 207:938. PubMed
  102. Saito S, et al. 2020. Nutrients. 12:. PubMed
  103. Hreha TN, et al. 2020. Front Immunol. 1.597916667. PubMed
  104. Sun T, et al. 2018. Front Immunol. 9:1245. PubMed
  105. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
  106. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  107. Dolgova EV, et al. 2022. Int J Mol Sci. 23:. PubMed
  108. Wang G, et al. 2021. Nat Commun. 12:5733. PubMed
  109. Bode K, et al. 2020. Cell Reports. 29(13):4435-4446.e9.. PubMed
  110. Kimura A, et al. 2018. J Exp Med. 215:2197. PubMed
  111. Jiang H, et al. 2018. Front Pharmacol. 9:612. PubMed
  112. Blank A, et al. 2021. J Pathol. 253:160. PubMed
  113. Li X, et al. 2014. PLoS One. 9:108192. PubMed
  114. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  115. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  116. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  117. Kornstädt L, et al. 2021. Front Immunol. 11:607048. PubMed
  118. Pandey V, et al. 2021. eLife. 0.416666666666667. PubMed
  119. Balashov L 2015. Mult Scler. 21: 1131-1138. PubMed
  120. Liang Y, et al. 2014. J Immunol. 192:1277. PubMed
  121. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  122. Wang J, et al. 2021. Nat Commun. 12:6198. PubMed
  123. Zhou Y, et al. 2020. Front Pharmacol. 10:1579. PubMed
  124. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  125. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  126. Li Y, et al. 2021. Sci Transl Med. 13:. PubMed
  127. Li X, et al. 2009. PLoS One. 4:e6385. PubMed
  128. Cheng Y, et al. 2020. PLoS Pathog. 16:e1008569. PubMed
  129. Ji W, et al. 2018. Evid Based Complement Alternat Med. 2017:3272649. PubMed
  130. Xiong W, et al. 2022. Adv Sci (Weinh). 9:e2103029. PubMed
  131. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  132. Gómez LA, et al. 2020. Front Microbiol. 11:1586. PubMed
  133. Benhamron S, et al. 2012. PLoS One. 7:e35602. PubMed
  134. Sanchez M et al. 2017. Cell host & microbe. 22(4):543-551 . PubMed
  135. Cianciaruso C, et al. 2020. Cell Reports. 27(10):3062-3080.e11.. PubMed
  136. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  137. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
  138. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  139. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  140. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  141. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  142. Zheng B, et al. 2021. Bioact Mater. 6:3879. PubMed
  143. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  144. Ren S, et al. 2022. Int J Biol Sci. 18:166. PubMed
  145. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  146. Nicolas-Boluda A, et al. 2021. eLife. 10:00. PubMed
  147. Wawrzyniak M, et al. 2021. Pharmacol Res Perspect. 9:e00837. PubMed
  148. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  149. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  150. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  151. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
  152. Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
  153. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  154. Funk KE, et al. 2021. Aging Cell. 20:e13412. PubMed
  155. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  156. Sadiq BA, et al. 2020. Current Protocols in Immunology. 131(1):e115. PubMed
RRID
AB_313126 (BioLegend Cat. No. 104705)
AB_313127 (BioLegend Cat. No. 104706)

Antigen Details

Structure
Ig superfamily, 60 kD
Distribution

Macrophages, activated B cells and T cells, dendritic cells

Function
T cell costimulation
Ligand/Receptor
CD28 (stimulatory), CD152(CTLA4) (inhibitory)
Cell Type
B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Linsley PS, et al. 1991. J. Exp. Med. 174:561.
3. Salomon B, et al. 2001. Annu. Rev. Immunol. 19:225.

Gene ID
12519 View all products for this Gene ID
UniProt
View information about CD80 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 02/18/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
16-10A1 (See other available formats)
Regulatory Status
RUO
Other Names
B7-1, B7, Ly-53
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
16-10A1
LPS-stimulated (3 days) BALB/c splenocytes stained with 16-10A1 FITC
  • 16-10A1
    LPS-stimulated (3 days) BALB/c splenocytes stained with 16-10A1 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
104705 50 µg DKK422
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104706 500 µg DKK1212
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD80 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD80 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD80 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD80 appears to be expressed later in the immune response than CD86. CD80 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Reported Reactivity
Dog
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
CHO cell line transfected with mouse B7 (CD80)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation2, in vitro and in vivo blocking of CTLA-4 Ig to CD80 by blocking costimulation of T cells by activated B cells2-4, and immunohistochemical staining of acetone-fixed frozen sections1,4. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104747-104752).

Application References
  1. Harlan DM, et al. 1994. P. Natl. Acad. Sci. USA 91:3137. (IHC)
  2. Razi-Wolf Z, et al. 1992. P. Natl. Acad. Sci. USA 89:4210. (Block, IP)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  5. Ma XT, et al. 2006. Cancer Res. 66:1169.
  6. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC)
  7. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  8. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  9. Misra RS, et al. 2010. J. Exp Med. 207:1775. PubMed
  10. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  11. Philipsen L, et al. 2013. Mol Cell Proteomics. 12:2551. PubMed
Product Citations
  1. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  2. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  3. Wang H, et al. 2022. J Nanobiotechnology. 20:513. PubMed
  4. Kimura Y, et al. 2023. Front Immunol. 14:1070196. PubMed
  5. Vesin B, et al. 2022. Mol Ther. 30:2984. PubMed
  6. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  7. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  8. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  9. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  10. Brigo N, et al. 2023. Cells. 12:. PubMed
  11. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  12. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  13. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  14. Kawai H, et al. 2021. Asian Pac J Allergy Immunol. :. PubMed
  15. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  16. Kis-Toth K, et al. 2011. J Immunol. 187:1273. PubMed
  17. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  18. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  19. Gravano D, et al. 2011. PLoS One. 6:e13517. PubMed
  20. Porciello N, et al. 2018. Nat Commun. 9:1080. PubMed
  21. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  22. Liang F, et al. 2021. RSC Adv. 11:35331. PubMed
  23. Matsumura F, et al. 2021. J Immunol. 207:938. PubMed
  24. Saito S, et al. 2020. Nutrients. 12:. PubMed
  25. Hreha TN, et al. 2020. Front Immunol. 1.597916667. PubMed
  26. Sun T, et al. 2018. Front Immunol. 9:1245. PubMed
  27. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
  28. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  29. Dolgova EV, et al. 2022. Int J Mol Sci. 23:. PubMed
  30. Wang G, et al. 2021. Nat Commun. 12:5733. PubMed
  31. Bode K, et al. 2020. Cell Reports. 29(13):4435-4446.e9.. PubMed
  32. Kimura A, et al. 2018. J Exp Med. 215:2197. PubMed
  33. Jiang H, et al. 2018. Front Pharmacol. 9:612. PubMed
  34. Blank A, et al. 2021. J Pathol. 253:160. PubMed
  35. Li X, et al. 2014. PLoS One. 9:108192. PubMed
  36. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  37. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  38. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  39. Kornstädt L, et al. 2021. Front Immunol. 11:607048. PubMed
  40. Pandey V, et al. 2021. eLife. 0.416666666666667. PubMed
  41. Balashov L 2015. Mult Scler. 21: 1131-1138. PubMed
  42. Liang Y, et al. 2014. J Immunol. 192:1277. PubMed
  43. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  44. Wang J, et al. 2021. Nat Commun. 12:6198. PubMed
  45. Zhou Y, et al. 2020. Front Pharmacol. 10:1579. PubMed
  46. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  47. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  48. Li Y, et al. 2021. Sci Transl Med. 13:. PubMed
  49. Li X, et al. 2009. PLoS One. 4:e6385. PubMed
  50. Cheng Y, et al. 2020. PLoS Pathog. 16:e1008569. PubMed
  51. Ji W, et al. 2018. Evid Based Complement Alternat Med. 2017:3272649. PubMed
  52. Xiong W, et al. 2022. Adv Sci (Weinh). 9:e2103029. PubMed
  53. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  54. Gómez LA, et al. 2020. Front Microbiol. 11:1586. PubMed
  55. Benhamron S, et al. 2012. PLoS One. 7:e35602. PubMed
  56. Sanchez M et al. 2017. Cell host & microbe. 22(4):543-551 . PubMed
  57. Cianciaruso C, et al. 2020. Cell Reports. 27(10):3062-3080.e11.. PubMed
  58. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  59. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
  60. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  61. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  62. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  63. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  64. Zheng B, et al. 2021. Bioact Mater. 6:3879. PubMed
  65. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  66. Ren S, et al. 2022. Int J Biol Sci. 18:166. PubMed
  67. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  68. Nicolas-Boluda A, et al. 2021. eLife. 10:00. PubMed
  69. Wawrzyniak M, et al. 2021. Pharmacol Res Perspect. 9:e00837. PubMed
  70. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  71. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  72. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  73. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
  74. Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
  75. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  76. Funk KE, et al. 2021. Aging Cell. 20:e13412. PubMed
  77. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  78. Sadiq BA, et al. 2020. Current Protocols in Immunology. 131(1):e115. PubMed
  79. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  80. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  81. Wang H, et al. 2022. J Nanobiotechnology. 20:513. PubMed
  82. Kimura Y, et al. 2023. Front Immunol. 14:1070196. PubMed
  83. Vesin B, et al. 2022. Mol Ther. 30:2984. PubMed
  84. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  85. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  86. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  87. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  88. Brigo N, et al. 2023. Cells. 12:. PubMed
  89. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  90. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  91. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  92. Kawai H, et al. 2021. Asian Pac J Allergy Immunol. :. PubMed
  93. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  94. Kis-Toth K, et al. 2011. J Immunol. 187:1273. PubMed
  95. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  96. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  97. Gravano D, et al. 2011. PLoS One. 6:e13517. PubMed
  98. Porciello N, et al. 2018. Nat Commun. 9:1080. PubMed
  99. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  100. Liang F, et al. 2021. RSC Adv. 11:35331. PubMed
  101. Matsumura F, et al. 2021. J Immunol. 207:938. PubMed
  102. Saito S, et al. 2020. Nutrients. 12:. PubMed
  103. Hreha TN, et al. 2020. Front Immunol. 1.597916667. PubMed
  104. Sun T, et al. 2018. Front Immunol. 9:1245. PubMed
  105. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
  106. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  107. Dolgova EV, et al. 2022. Int J Mol Sci. 23:. PubMed
  108. Wang G, et al. 2021. Nat Commun. 12:5733. PubMed
  109. Bode K, et al. 2020. Cell Reports. 29(13):4435-4446.e9.. PubMed
  110. Kimura A, et al. 2018. J Exp Med. 215:2197. PubMed
  111. Jiang H, et al. 2018. Front Pharmacol. 9:612. PubMed
  112. Blank A, et al. 2021. J Pathol. 253:160. PubMed
  113. Li X, et al. 2014. PLoS One. 9:108192. PubMed
  114. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  115. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  116. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  117. Kornstädt L, et al. 2021. Front Immunol. 11:607048. PubMed
  118. Pandey V, et al. 2021. eLife. 0.416666666666667. PubMed
  119. Balashov L 2015. Mult Scler. 21: 1131-1138. PubMed
  120. Liang Y, et al. 2014. J Immunol. 192:1277. PubMed
  121. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  122. Wang J, et al. 2021. Nat Commun. 12:6198. PubMed
  123. Zhou Y, et al. 2020. Front Pharmacol. 10:1579. PubMed
  124. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  125. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  126. Li Y, et al. 2021. Sci Transl Med. 13:. PubMed
  127. Li X, et al. 2009. PLoS One. 4:e6385. PubMed
  128. Cheng Y, et al. 2020. PLoS Pathog. 16:e1008569. PubMed
  129. Ji W, et al. 2018. Evid Based Complement Alternat Med. 2017:3272649. PubMed
  130. Xiong W, et al. 2022. Adv Sci (Weinh). 9:e2103029. PubMed
  131. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  132. Gómez LA, et al. 2020. Front Microbiol. 11:1586. PubMed
  133. Benhamron S, et al. 2012. PLoS One. 7:e35602. PubMed
  134. Sanchez M et al. 2017. Cell host & microbe. 22(4):543-551 . PubMed
  135. Cianciaruso C, et al. 2020. Cell Reports. 27(10):3062-3080.e11.. PubMed
  136. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  137. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
  138. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  139. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  140. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  141. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  142. Zheng B, et al. 2021. Bioact Mater. 6:3879. PubMed
  143. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  144. Ren S, et al. 2022. Int J Biol Sci. 18:166. PubMed
  145. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  146. Nicolas-Boluda A, et al. 2021. eLife. 10:00. PubMed
  147. Wawrzyniak M, et al. 2021. Pharmacol Res Perspect. 9:e00837. PubMed
  148. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  149. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  150. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  151. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
  152. Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
  153. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  154. Funk KE, et al. 2021. Aging Cell. 20:e13412. PubMed
  155. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  156. Sadiq BA, et al. 2020. Current Protocols in Immunology. 131(1):e115. PubMed
RRID
AB_313126 (BioLegend Cat. No. 104705)
AB_313127 (BioLegend Cat. No. 104706)

Antigen Details

Structure
Ig superfamily, 60 kD
Distribution

Macrophages, activated B cells and T cells, dendritic cells

Function
T cell costimulation
Ligand/Receptor
CD28 (stimulatory), CD152(CTLA4) (inhibitory)
Cell Type
B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Linsley PS, et al. 1991. J. Exp. Med. 174:561.
3. Salomon B, et al. 2001. Annu. Rev. Immunol. 19:225.

Gene ID
12519 View all products for this Gene ID
UniProt
View information about CD80 on UniProt.org
Go To Top Version: 2    Revision Date: 02/18/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account